Generic · Tablet
Tolcapone 100 mg tablet price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for tolcapone 100 mg tablet this week. The makers, package codes, recalls and label are below.
What people paid for tolcapone 100 mg tablet
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Every manufacturer and package code
2 companies sell tolcapone 100 mg tablet under 2 package codes (NDCs).
| Maker | Package codes | Per unit |
|---|---|---|
| Ingenus Pharmaceuticals, LLC | 50742-193-90 | - |
| Oceanside Pharmaceuticals | 68682-938-90 | - |
All 2 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Official label & what changed
Tolcapone Tablets, USP
WARNING
Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections).
Because of the risk of liver injury and because tolcapone tablets, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets.
Tolcapone tablets therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).
PATIENTS WHO DEVELOP EVIDENCE OF HEPATOCELLULAR INJURY WHILE ON TOLCAPONE TABLETS AND ARE WITHDRAWN FROM THE DRUG FOR ANY REASON MAY BE AT INCREASED RISK FOR LIVER INJURY IF TOLCAPONE TABLETS IS REINTRODUCED. ACCORDINGLY, SUCH PATIENTS SHOULD NOT ORDINARILY BE CONSIDERED FOR RETREATMENT.
Cases of severe hepatocellular injury, including fulminant liver failure resulting in death, have been reported in postmarketing use. As of May 2005, 3 cases of fatal fulminant hepatic failure have been reported from more than 40,000 patient years of worldwide use. This incidence may be 10-to100-fold higher than the background incidence in the general population. Underreporting of cases may lead to significant underestimation of the increased risk associated with the use of tolcapone tablets. All 3 cases were reported within the first six months of initiation of treatment with tolcapone tablets. Analysis of the laboratory monitoring data in over 3,400 tolcapone tablets-treated patients participating in clinical trials indicated that increases in SGPT/ALT or SGOT/AST, when present,generally occurred within the first 6 months of treatment with tolcapone tablets.
A prescriber who elects to use tolcapone tablets in face of the increased risk of liver injury is strongly advised to monitor patients for evidence of emergent liver injury. Patients should be advised of the need for self-monitoring for both the classical signs of liver disease (e.g., clay colored stools, jaundice) and the nonspecific ones (eg, fatigue, loss of appetite, lethargy).
Although a program of periodic laboratory monitoring for evidence of hepatocellular injury is recommended, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.
Before starting treatment with tolcapone tablets, the physician should conduct appropriate tests to exclude the presence of liver disease. In patients determined to be appropriate candidates for treatment with tolcapone tablets, serum glutamic-pyruvic transaminase (SGPT/ALT) and serum glutamic-oxaloacetic transaminase (SGOT/AST) levels should be determined at baseline and periodically (i.e. every 2 to 4 weeks) for the first 6 months of therapy. After the first six months, periodic monitoring is recommended at intervals deemed clinically relevant. Although more frequent monitoring increases the chances of early detection, the precise schedule for monitoring is a matter of clinical judgment. If the dose is increased to 200 mg tid (see DOSAGE AND ADMINISTRATION section), liver enzyme monitoring should take place before increasing the dose and then be conducted every 2 to 4 weeks for the following 6 months of therapy. After six months, periodic monitoring is recommended at intervals deemed clinically relevant.
Tolcapone tablets should be discontinued if SGPT/ALT or SGOT/AST levels exceed 2 times the upper limit of normal or if clinical signs and symptoms suggest the onset of hepatic dysfunction (persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, and right upper quadrant tenderness).
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about tolcapone 100 mg tablet
Who makes tolcapone 100 mg tablet?
2 companies: Ingenus Pharmaceuticals, LLC, Oceanside Pharmaceuticals. See every package code.
Is tolcapone in shortage?
No shortage is reported right now. We check every day.
Has tolcapone been recalled?
No recalls are on record.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about tolcapone 100 mg tablet
No comments yet. Questions, tips, what worked for you - start the conversation.